Serum erythropoietin and circulating BFU-E in patients with multiple myeloma and anaemia but without renal failure.
In 30 patients with multiple myeloma (MM) and mild to moderate anaemia (mean Hb 107 g/l, 95% confidence limit (CL) 102-113) but no evidence of renal failure (serum creatinine < 110 mumol/l), serum erythropoietin (EPO) showed significant inverse logarithmic correlation with the haemoglobin level (r = -0.57, p = 0.001). The observed/expected ratio of log-EPO in patients with MM (mean 0.96, CL 0.89-1.04) was similar to that of 119 subjects (mean 1.01, CL 0.96-1.05) with or without anaemia (mean Hb 116 g/L, CL 110-121) but without renal failure. The concentration of circulating erythroid progenitors (BFU-E) in 10 MM patients in plateau phase was significantly reduced (mean 0.70 x 10(5)/l of blood, CL 0.34-1.06) compared to that of 8 normal controls (mean 3.57, CL 1.60-5.55, p = 0.011) In vitro sensitivity of the BFU-E to EPO in the patients with MM was comparable to that of the normal controls. It appears that in MM there is an appropriate EPO response to anaemia but even in the plateau phase the number of circulating BFU-E is reduced, reflecting a degree of marrow failure. However, the progenitors are normally sensitive to EPO in such patients, and therapeutic doses of EPO may correct the anaemia by a pharmacological rather than a physiological effect.
Majumdar
G
G
Division of Haematology, UMDS, London, England.
Westwood
N B
NB
Bell-Witter
C
C
Muggleston
D
D
Phillips
J
J
Pearson
T C
TC
D000740:Anemia / Q000097:blood / Q000209:etiology* / Q000628:therapy; D001772:Blood Cell Count; D015672:Erythroid Precursor Cells; D004921:Erythropoietin / Q000008:administration & dosage / Q000097:blood* / Q000627:therapeutic use; D006454:Hemoglobins / Q000032:analysis; D006801:Humans; D007155:Immunologic Factors / Q000008:administration & dosage / Q000627:therapeutic use; D009101:Multiple Myeloma / Q000097:blood* / Q000150:complications; D011994:Recombinant Proteins / Q000008:administration & dosage / Q000627:therapeutic use; D051437:Renal Insufficiency
D006454:Hemoglobins; D007155:Immunologic Factors; D011994:Recombinant Proteins; D004921:Erythropoietin